论文部分内容阅读
目的研究脑动静脉畸形(cerebral arteriovenous malformation,cAVM)患者外周血中可溶性E-选择素和P-选择素的表达水平,及其与畸形血管团破裂的关系。方法 30例cAVM患者根据有无出血史分为未破裂组和破裂组,同时随机取10位健康体检者作为对照组。采集各入组样本外周血进行酶联免疫吸附试验(ELISA),检测可溶性E-选择素和P-选择素的表达水平。结果 cAVM未破裂组、cAVM破裂组与对照组相比外周血可溶性E-选择素表达[(35.20±7.94),(55.90±18.95)vs.(20.00±8.98)ng/ml,P=0.001、0.002]显著升高,与未破裂组相比,破裂组cAVM可溶性E-选择素水平明显升高(P=0.023);cAVM破裂组和未破裂组外周血可溶性P-选择素水平与对照组相比差异无统计学意义[(60.80±18.88)、(63.00±19.39)vs.(45.25±17.30)ng/ml,P=0.056、0.091],cAVM破裂组与未破裂组比较差异亦无统计学意义(P=0.794)。结论 cAVM患者外周血可溶性E-选择素水平与畸形血管的破裂具有相关性,作为内皮细胞损伤的标志外周血可溶性E-选择素表达水平可能成为评估cAVM破裂风险的分子生物学标记物。
Objective To investigate the expression of soluble E-selectin and P-selectin in peripheral blood of patients with cerebral arteriovenous malformation (cAVM) and their relationship with the rupture of the abnormal vascular mass. Methods Thirty patients with cAVM were divided into rupture group and rupture group according to the presence or absence of bleeding, and 10 healthy subjects were randomly selected as the control group. Peripheral blood samples of each group were collected for enzyme-linked immunosorbent assay (ELISA) to detect the expression of soluble E-selectin and P-selectin. Results The expression of soluble E-selectin in cAVM unruptured group and cAVM ruptured group was significantly higher than that in control group [(35.20 ± 7.94), (55.90 ± 18.95) vs. (20.00 ± 8.98) ng / ml, P = 0.001,0.002 ], The level of soluble E-selectin of cAVM in ruptured group was significantly higher than that of non-ruptured group (P = 0.023). The levels of soluble P-selectin in cAVM ruptured group and non-ruptured group were significantly higher than those in control group There was no significant difference between cAVM rupture group and non-rupture group (60.80 ± 18.88 vs 63.00 ± 19.39 vs. 45.25 ± 17.30 ng / ml, P = 0.056, 0.091) P = 0.794). Conclusions The level of soluble E-selectin in peripheral blood of cAVM patients is correlated with the rupture of abnormal vessels. The expression of soluble E-selectin in peripheral blood as a marker of endothelial cell injury may be a molecular biomarker for assessing the risk of cAVM rupture.